The German conglomerate BayWa is confronting a perfect storm of legal, regulatory, and financial challenges, casting severe doubt on its ambitious turnaround strategy. With critical fourth-quarter results due in just five days, the company’s entire future hangs in the balance.
Legal and Regulatory Scrutiny Intensifies
At the forefront of its troubles are formal investigations by Munich I public prosecutor’s office. Prosecutors are examining allegations of breach of trust against several former executives, including ex-CEOs Klaus Josef Lutz and Marcus Pöllinger. The core accusation is that previous leadership systematically concealed the risks within the heavily indebted group. Searches of private premises have already been conducted. All accused individuals are presumed innocent.
In a parallel development, German financial watchdog BaFin has formally criticized BayWa’s 2023 annual report. The regulator found that the company failed to disclose material financing risks in its management report. Specifically omitted were the terms of a billion-euro credit facility, alongside refinancing risks for a €500 million bond and short-term promissory notes worth €632 million. This rebuke also implicitly targets auditor PwC, which had issued an unqualified audit opinion for those accounts.
Asset Sale Fails to Bridge Massive Funding Gap
A central pillar of the debt reduction plan is the disposal of BayWa’s 74% stake in New Zealand-based fresh produce marketer T&G Global. The business, which employs approximately 1,600 people and markets apples, tomatoes, and citrus fruits in over 60 countries, generated $1.3 billion in revenue in 2024. Insiders anticipate proceeds of around €300 million from the sale—a sum that pales in comparison to the total financial shortfall.
Should investors sell immediately? Or is it worth buying BayWa?
The epicenter of the crisis, however, is the renewable energy subsidiary BayWa r.e. Shifting energy policies in the United States have severely depressed achievable sale values, rendering the originally projected €1.7 billion price tag for a 51% stake unrealistic. The adjusted EBITDA target for this division has already been slashed to approximately €140 million by 2027; an initial expert report had projected €230 million for 2028. Consequently, the planning horizon for the unit’s recovery has been pushed out to 2030.
Amid this turmoil, the group is undergoing a profound structural contraction. Plans call for the elimination of roughly 1,300 positions by 2027, with the central administration facing a 40% reduction in headcount. Twenty-six branch offices are slated for closure, and group revenue is projected to be scaled back to about €10 billion by 2028.
Forbearance Agreement Hinges on Forthcoming Results
The imminent release of Q4 figures is far from a routine disclosure. Creditor banks and major shareholders are currently negotiating a forbearance agreement that would extend until autumn 2026. This pact is intended to grant BayWa the necessary breathing room to fundamentally revise its restructuring concept. Should this extension fail, management would be forced to present creditors with a completely new plan—a daunting task given the original strategy’s apparent failure.
BayWa does not expect to publish its complete 2025 annual report until the fourth quarter of 2026, and the company has already withdrawn its financial guidance for 2026. Reflecting persistent investor unease, the share price currently trades approximately 14% below its 200-day moving average.
Ad
BayWa Stock: Buy or Sell?! New BayWa Analysis from March 22 delivers the answer:
The latest BayWa figures speak for themselves: Urgent action needed for BayWa investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 22.
BayWa: Buy or sell? Read more here...









